Jeffrey Keats

2.4k total citations
12 papers, 402 citations indexed

About

Jeffrey Keats is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Jeffrey Keats has authored 12 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Genetics and 5 papers in Hematology. Recurrent topics in Jeffrey Keats's work include Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Fungal Plant Pathogen Control (2 papers). Jeffrey Keats is often cited by papers focused on Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Fungal Plant Pathogen Control (2 papers). Jeffrey Keats collaborates with scholars based in United States and Spain. Jeffrey Keats's co-authors include William C. Shakespeare, Yihan Wang, Chester A. Metcalf, David C. Dalgarno, Raji Sundaramoorthi, Tomi K. Sawyer, Victor M. Rivera, Tim Clackson, Regine S. Bohacek and Brian Druker and has published in prestigious journals such as Blood, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Jeffrey Keats

11 papers receiving 388 citations

Peers

Jeffrey Keats

HEMAT

ONCOL

GENET

PRM

Krista Fager United States

Amy Camuso United States

Mei-Li Wen United States

Tri K. Nguyen United States

B. Laffranchi Italy

Roberta Rostagno Italy

Daisy Moreno United States

Danielle Cain United States

Josephine L. Klitgaard United States

Eva Eckelhart Austria

Krista Fager United States

Jeffrey Keats

113 ×0.6

161 ×1.0

HEMAT

135 ×0.9

ONCOL

114 ×1.0

GENET

72 ×0.7

PRM

Citations per year, relative to Jeffrey Keats Jeffrey Keats (= 1×) peers Krista Fager

Countries citing papers authored by Jeffrey Keats

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Keats's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Keats with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Keats more than expected).

Fields of papers citing papers by Jeffrey Keats

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Keats. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Keats. The network helps show where Jeffrey Keats may publish in the future.

Co-authorship network of co-authors of Jeffrey Keats

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Keats. A scholar is included among the top collaborators of Jeffrey Keats based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Keats. Jeffrey Keats is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Keats, Jeffrey, Weiqing Chen, Cuyue Tang, et al.. (2021). Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma. Cancer Research. 81(13_Supplement). 1161–1161. 3 indexed citations

Keats, Jeffrey, et al.. (2019). Abstract B011: Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion. Molecular Cancer Therapeutics. 18(12_Supplement). B011–B011. 1 indexed citations

Raimondi, Alejandra, Christine R. Klaus, Jeffrey Keats, et al.. (2015). Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in MLL-rearranged leukemia cell lines. Molecular Cancer Therapeutics. 14(12_Supplement_2). B82–B82. 2 indexed citations

Rivera, Victor M., Frank Wang, Rana Anjum, et al.. (2012). Abstract 1794: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Research. 72(8_Supplement). 1794–1794. 36 indexed citations

Zhang, Sen, Frank Wang, Jeffrey Keats, et al.. (2010). Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Cancer Research. 70(8_Supplement). LB–298. 44 indexed citations

Rivera, Victor M., Qihong Xu, Lori Berk, et al.. (2008). Potent Antitumor Activity of AP24534, An Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML). Blood. 112(11). 2932–2932. 7 indexed citations

Rivera, Victor M., Qihong Xu, Frank Wang, et al.. (2007). Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).. Blood. 110(11). 1032–1032. 15 indexed citations

Summy, Justin M., José G. Treviño, Donald P. Lesslie, et al.. (2005). AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Molecular Cancer Therapeutics. 4(12). 1900–1911. 73 indexed citations

Metcalf, Chester A., Regine S. Bohacek, Leonard W. Rozamus, et al.. (2004). Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy.. Cancer Research. 64. 573–573. 19 indexed citations

10.

O’Hare, Thomas, Roy M. Pollock, Eric P. Stoffregen, et al.. (2004). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 104(8). 2532–2539. 151 indexed citations

11.

Sundaramoorthi, Raji, William C. Shakespeare, Terence P. Keenan, et al.. (2003). Bone-Targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues. Bioorganic & Medicinal Chemistry Letters. 13(18). 3063–3066. 14 indexed citations

12.

Wang, Yihan, Chester A. Metcalf, William C. Shakespeare, et al.. (2003). Bone-Targeted 2,6,9-Trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorganic & Medicinal Chemistry Letters. 13(18). 3067–3070. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact